Melbourne’s Amplia Therapeutics is teaming up with Eli Lilly to test a powerful new combo therapy for advanced lung cancer—pairing Amplia’s FAK-targeting drug narmafotinib with Lilly’s KRAS inhibitor olomorasib. Set to launch in late 2026, this phase 1/2 trial aims to overcome treatment resistance and boost survival rates, with Amplia leading the global study and Lilly supplying their drug at no cost. Backed by promising pancreatic cancer results, this partnership could catapult Amplia onto the world stage as a key player in next-gen cancer therapies.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
